RU99109596A - APPLICATION OF H +, K + -ATTASE INHIBITOR FOR THE TREATMENT OF NOSE POLYPES - Google Patents

Claims (18)

1. The use of an inhibitor of H ⁺ , K ⁺ -ATPase in the manufacture of drugs for the treatment of nasal polyps. 2. The use of an inhibitor of H ⁺ , K ⁺ -ATPase in the manufacture of drugs for the treatment of Widal syndrome. 3. The use of an inhibitor of H ⁺ , K ⁺ -ATPase and glucocorticoid in the manufacture of a pharmaceutical preparation intended for simultaneous, separate or sequential administration in the treatment of Widal syndrome. 4. The use of an inhibitor of H ⁺ , K ⁺ -ATPase and glucocorticoid in the manufacture of a pharmaceutical preparation intended for simultaneous, separate or sequential administration in the treatment of asthma.  5. The use according to any one of claims 3 and 4, where the glucocorticoid is an anti-inflammatory steroid with local activity.  6. The use according to claim 5, wherein the glucocorticoid is budesonide, beclomethasone dipropionate or fluticasone propionate. 7. The use according to any one of claims 1 to 6, where the inhibitor of H ⁺ , K ⁺ -ATPase is a compound of formula I

where het ₁ is

or

Het ₂ is

X is

where N in the benzimidazole group Het ₂ means that one of the ring carbon atoms substituted by R ₆ - R ₉ may possibly be replaced by a nitrogen atom without any substituents;
R ₁ and R _{3 are} each independently hydrogen, alkyl or alkoxy, provided that R ₁ and R _{3 are} not alkoxy at the same time; and R ₂ is alkyl, alkoxy, possibly substituted by fluorine, alkylthio or alkoxyalkoxy; or one of R ₁ and R ₃ is halogen and the other is hydrogen, and R ₂ is 1-morpholino, 1-piperidino or dialkylamino;
R ₄ and R ₅ are the same or different and are selected from hydrogen and alkyl;
R ₆ - R ₉ are the same or different and are selected from hydrogen, halogen, alkyl, alkoxy, haloalkoxy, alkylcarbonyl and alkoxycarbonyl;
R ₁₀ is hydrogen, or R ₁₀ and R ₃ together form a ring containing from 6 to 8 carbon atoms; and
R ₁₁ represents hydrogen, halogen or alkyl;
where the compound of formula (I) may be in the form of a pharmaceutically acceptable alkaline salt or in neutral form, or is a separate enantiomer or their racemic mixture;
where each alkyl or alkylenyl moiety has a branched or straight chain and contains from 1 to 6 carbon atoms. 8. The use according to claim 7, where the compound of formula (I) is a compound of formula Ia

or its alkali salt, or (-) - enantiomer, or alkali salt (-) - enantiomer. 9. A method of treating nasal polyps in which a subject suffering from this condition is treated with a pharmaceutical preparation containing an inhibitor of H ⁺ , K ⁺ -ATPase. 10. A method of treating Widal syndrome in which a subject suffering from this syndrome is treated with a pharmaceutical preparation containing an inhibitor of H ⁺ , K ⁺ -ATPase. 11. A method of treating Widal syndrome, in which a subject who is suffering from this syndrome simultaneously, separately or sequentially is administered a pharmaceutical preparation containing an inhibitor of H ⁺ , K ⁺ -ATPase and a glucocorticoid. 12. A method of treating asthma in which a subject who is suffering from this syndrome simultaneously, separately or sequentially is administered a pharmaceutical preparation containing an inhibitor of H ⁺ , K ⁺ -ATPase and a glucocorticoid.  13. The method according to claim 11, wherein the glucocorticoid is a glucocorticoid, as defined in claim 5 or 6. 14. The method according to any of paragraphs.9-13, characterized in that the inhibitor of H ⁺ , K ⁺ -ATPase is a compound of the formula defined in paragraph 7 or 8. 15. Pharmaceutical preparation for simultaneous, separate or sequential use in the treatment of Widal syndrome, containing an inhibitor of H ⁺ , K ⁺ -ATPase and glucocorticoid. 16. Pharmaceutical preparation for simultaneous, separate or sequential administration in the treatment of asthma, containing an inhibitor of H ⁺ , K ⁺ -ATPase and glucocorticoid.  17. The pharmaceutical preparation according to claim 15 or 16, characterized in that the glucocorticoid is a glucocorticoid, as defined in paragraph 5 or 6. 18. The pharmaceutical preparation according to any one of claims 15-17, wherein the H ⁺ , K ⁺ -ATPase inhibitor is a compound of the formula as defined in claim 7 or 8.